ArticleHuman mutation2026
SRSF1/Mcl-1 Axis Drives Apoptosis Evasion and Shapes the Immune Microenvironment to Promote Gastric Cancer Progression.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is one of the malignancies with the highest incidence and mortality worldwide. Evasion of apoptosis is a hallmark of cancer that drives tumor progression. The splicing factor SRSF1 and antiapoptotic protein Mcl-1, including its isoforms Mcl-1L and Mcl-1S, play significant roles in cancer development; however, the regulatory mechanisms of the SRSF1-Mcl-1 axis in GC remain unclear. This study systematically evaluated the function of SRSF1 in GC by integrating multidatabase analyses (TIMER, UALCAN, and KM-Plotter), in vitro experiments (qRT-PCR, Western blot, Transwell migration/invasion, and apoptosis assays), in vivo xenograft models, and bioinformatic approaches (single-cell RNA sequencing, hdWGCNA, cell interaction analysis, and mutational analysis). SRSF1 is significantly overexpressed in GC tissues and cell lines, correlating with poor prognosis in patients. Through comprehensive multiomics analysis, we first revealed that SRSF1-positive malignant epithelial cells possess a unique coexpression network and exhibit significantly enhanced interactions with fibroblasts, reshaping the tumor microenvironment (TME). Subsequently, functional assays demonstrated that SRSF1 overexpression enhances cell invasion, migration, and apoptosis resistance by inhibiting the proapoptotic isoform Mcl-1S and suppressing the mitochondrial apoptosis pathway (Bak/caspase-9/caspase-3). In conclusion, the SRSF1-Mcl-1 axis serves as a dual key regulator of invasion/migration and apoptosis evasion in GC, providing a new strategy for targeted therapy in advanced GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.